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Aims. We have audited the changes in treatment practice for small-cell lung cancer (SCLC) presented to a single multidisciplinary
team (MDT) at Doncaster and Bassetlaw Hospitals between January 1998 and December 2005. Materials and Methods.T h e
MDT database was used to identify all patients with SCLC. Anonymised demographic, treatment, and outcome details were
extractedfromthedatabasesupplementedbypatientrecords.Results.235patientswereidentiﬁed.112(48%)hadlimiteddiseaseat
presentation.Chemotherapywastheinitialtreatmentfor195patients,77%ofwhomhadadocumentedradiologicalresponsewith
a complete response in 24%. Chemotherapy regimes evolved during the study period with the increasing use of platinum-based
chemotherapy. Anthracycline-based chemotherapy was most used before 2004 and was given to 57% of all patients. 42% received
consolidation thoracic radiotherapy and 24% prophylactic cranial irradiation. The median and 2-year survival were 8 months
and 18%, respectively, for patients with limited disease and 5 months and 5%, respectively, for extensive disease. Conclusion.W e
have documented changes in treatment practice and service delivery of SCLC over the 8 years during which the MDT has been
operating. However, there has not achieve any signiﬁcant improvement in outcome for the population of patients with SCLC.
Copyright © 2008 Loaie M. El-Helw et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
It has been recognised that cancer survival in the UK has
lagged behind the USA and other European countries.
This recognition triggered the Calman-Hine report in the
mid 1990s, which started a major reorganisation of cancer
services in the UK. In 1998, the NHS executive published
guidance on Improving Outcomes in Lung Cancer [1].
One aspect of this guidance examined was the eﬀectiveness
of multidisciplinary teams (MDTs) and supported the
recommendation that all patients with lung cancer have
their case reviewed by a specialist MDT and targeted
investment was made to develop team working. In 2000,
the NHS cancer plan looked to introduce more radical
changes and cover the whole cancer care pathway. This led to
signiﬁcant investment aimed at reducing waiting times and
improving access to treatment.
The Doncaster lung cancer MDT was set up and in 1997
started to review the management of all patients with lung
cancer who presented to three district general hospitals that
cover a population of 450000 patients in South Yorkshire
and North Nottinghamshire . From the outset, a database
was designed to prospectively record data for all patients
reviewed by the MDT and included demographic, staging,
and treatment details. The MDT has now been operational
for 10 years and we have started to review our experience
over that time particularly looking to document the trends
in treatment and outcome that have occurred during this
period of cancer service reorganisation in the UK.
This paper has looked speciﬁcally at patients with small-
cell lung cancer (SCLC) which compromises approximately
20% of all cases of lung cancer. The disease is characterised
by early metastatic spread, sensitivity to chemotherapy, and
early development of resistance [2]. Untreated the median
survival in limited stage is 3 months, and in extensive stage
1.5 months. With single-agent chemotherapy, trials indicate
a median survival of 6 and 4 months and with combination
chemotherapy, 10–20 and 7–11 months, respectively [3–6].2 Journal of Oncology
Improving outcomes in lung cancer, published in 1998,
[1] reviewed the research evidence and recommended the
use of combination chemotherapy. This guidance was able to
suggest an optimal duration of chemotherapy but concluded
there was little clear evidence to guide the choice of drugs.
The guidance also felt there was suﬃcient evidence to
support the use of thoracic radiotherapy and prophylactic
cranial irradiation in limited stage disease. The National
Institute for Clinical Excellence commissioned an update,
which was published as the “The Diagnosis and Treatment
of Lung Cancer Guidelines” in 2005 [7]. This guidance built
on the previous recommendation indicating the superiority
of platinum-based chemotherapy as ﬁrst line treatment
and indicating a role for second line treatment in selected
patients.Nonewrecommendationsweremadeforradiother-
apy, though its timing and sequencing with chemotherapy
was discussed.
Therefore, we have chosen to study the whole population
of patients with SCLC presenting to our MDT and audit the
changes in treatment practice that have occurred between
1998 and 2005 and monitored the eﬀect that the investment
made following the NHS cancer plan has had an outcome.
2.MaterialsandMethods
The MDT database has prospectively recorded all patients
with a histological or radiological diagnosis of lung cancer
since the Doncaster Lung cancer MDT was formed. This
database has been used to identify all patients with a
conﬁrmed histological diagnosis of SCLC between January
1998 and December 2005. The demographic and treatment
data on the database, supplemented by information from
the patient records, has been anonymised and subjected to
statistical analysis. To examine for time trends we divided
patientsinto 3chronologicalgroups(1998–2000, 2001-2002,
and 2003–2005) each containing approximately 80 patients.
Kaplan Myer survival analysis was performed using SPSS
statistical package version 12.0.1.
2.1. Patients Characteristics. Two hundreds and thirty ﬁve
patients with SCLC were identiﬁed; 120 (51%) females and
115 (49%) males. The median age was 66 years (range 25–
87), there were 83 patients (35%) ≥70 years old at the time
of diagnosis. A histological diagnosis was made at ﬂexible
bronchoscopy in 83%, the remaining 17% required ﬁne
needle aspiration for cytology or CT guided biopsy.
110 patients had a performance status of 0 or 1 at
diagnosis and staging investigations showed 112 patients had
limited stage disease conﬁned to the ipislateral lung and
mediastinum. Applying the Manchester prognostic scoring
system [8], 91 patients (39%) fell into the good prognosis
category, 122 (52%) the intermediate, and 22 (9%) were in
the poor prognosis group.
We analysed the time from GP referral to starting
deﬁnitive treatment as a measure of the early diagnostic part
of the patient pathway. The duration was shortest between
2003–2005 compared to those of 2001-2002 and 1998–2000
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Figure 1: Mean time from referral to treatment.
(mean 27, 37, and 34 days and median of 26, 33, and 31 days,
resp.) (P<. 001 using one way ANOVA test) (Figure 1).
In Table 1, the patient characteristics and treatment
outcome are summarised and broken down into the three
chronological groups. For 83% of patients the initial
treatment was chemotherapy. The table also shows that
anthracycline-based chemotherapy was most commonly
used overall, though over the study period there was
increasing use of platinum-based treatment, which became
the most commonly used treatment in the last three years
of the study. The median number of chemotherapy cycles
given was 6 (range 1–6) and seventeen patients received
chemotherapy as part of ongoing clinical trials.
The table also indicates that the use of radiotherapy
was constant over the study period. Around 5% of patients
received radiotherapy as initial palliative treatment and in
a further 18% it was used to palliate symptoms later in the
course of the disease. Consolidation thoracic radiotherapy
(TRT) was given in 42% of patients who had shown a
responsetotheinitialchemotherapyandprophylacticcranial
irradiation(PCI)wasgivento24%ofpatientswhopresented
withlimitedstagediseaseandrespondedtochemotherapyor
were treated in the trial setting.
3. Results
3.1. Response. A Total 196 patient received primary chemo-
therapy, 5 died following the ﬁrst cycle of treatment leaving
191 assessable for response (Table 2). There was an overall
response rate was 77% (24% CR and 53% PR) with only
6% having documented progressed during chemotherapy.
We found a higher response rate for patients with limited
disease, performance status 0/1, and those less than 70
years old but none reached statistical signiﬁcance (using chi-
square test, P-values were 0.090, 0.390, 0.702, resp.). There
was higher response rate with platinum-based treatments
(87%) compared anthracycline (78%). The high response
rate for platinum-based treatment includes patients in the
poor prognostic group, particularly those with impaired
hepatic function, in whomsingle-agentcarboplatin wasused
and had a response rate of 50%.Journal of Oncology 3
Table 1: Patients characteristics and treatment outcome over the study period.
Variables Number of patients (%) Total no. (%)
Years (inclusive)
January 1998
till December
2000
January 2001
till December
2002
January 2003
till December
2005
Patients number 76 82 77 235
Gender
Females 35 (46) 44 (54) 41 (53) 120 (51)
Males 41 (54) 38 (46) 36 (47) 115 (49)
Stage
LD 39 (51) 38 (46) 35 (45) 112 (48)
ED 37 (49) 44 (54) 42 (55) 123 (52)
Mean time from referral to starting treatment (days) 34 37 27 Overall 31
Treatment
Chemotherapy 63 (83) 68 (83) 64 (83) 195 (83)
Palliative RT 4 (5) 5 (6) 4 (5) 13 (5.5)
Supportive Care 8 (11) 9 (11) 9 (12) 26 (11)
Resection and chemotherapy 1 (1) — — 1 (0.5)
Chemoregimens
Anthracycline based 38 (59) 43 (63) 30 (47) 111 (57)
Platinum based 14 (22) 25 (37) 34 (53) 73 (37)
Others 12 (19) — — 12 (6)
Radiotherapy
PCI 19 (33) 20 (35) 18 (32) 57 (24)
Consolidation TRT 32 (32.4) 33 (33.3) 34 (34.3) 99 (42)
To Metastases 9 (21) 22 (51) 12 (28) 43 (18)
Median survival
For all patients (m) 4876 ( P = .143)
For patients with LD (m) 781 0 8 ( P = .516)
For patients with ED (m) 3655 ( P = .006)
P-values were calculated using logrank test
LD: limited disease, ED: extensive disease, RT: radiotherapy, PCI: prophylactic cranial irradiation, TRT: thoracic radiotherapy, m: months.
3.2. Survival. The overall median survival, and 2- and 5-year
survival rates for all patients were 6 months, 8%, and 2%,
respectively.Inlimitedstagedisease,survivalswere8months,
15%, and 5%, respectively, and in extensive stage disease 5
months,5%,and0%,respectivelyfor(P<. 0001).Univariate
analysis also showed good Manchester prognostic group
(Figure 2) and chemotherapy response to be associated with
improved survival, but no signiﬁcant survival diﬀerences
were seen with age, sex, and year of treatment (Figure 3).
3.3. Toxicity. Five patients (2.5%) died in the 3 weeks that
followed the ﬁrst cycle of chemotherapy, and were recorded
as treatment related deaths. Case-notes review indicated
14% were admitted for the treatment of neutropenic sepsis
episodes, with this complication being more common with
anthracycline-based treatment (10%) than platinum (4%).
3.4. Relapse. 183 patients (96%) relapsed after primary
chemotherapy treatment, mostly with metastatic recurrence
(70%), 40% of the patients received second line chemother-
apy which included CAV regimen, single-agent carboplatin
or carboplatin/etoposide +/− palliative radiotherapy. The
median survival following second line treatment was 2
months (range 1–12 months).
4. Discussion
The Doncaster MDT serves an area with signiﬁcantly higher
rates of lung cancer incidence and mortality than the
national average; the indirectly standardised registration rate
(SRR) (2001–2003) for Doncaster was 138 for men and 140
for women [9]. Overall the standardised mortality ratios
(SMR) in Doncaster area were 114, 112 for males and
females, respectively, which are among the highest SMR
in England and Wales [10]. This indicates a poor general
health status for the population in the Doncaster area,
which would be expected to have an eﬀect on outcome
following a diagnosis of small-cell lung cancer in various
ways. Our population of patients with SCLC will be diﬀerent
to the population of patients entering the trials that provides4 Journal of Oncology
Table 2: Response to chemotherapy among 191 assessable patients.
Response, no. (%) Total
CR PR SD PD
Variable
Overall response 46 (24) 101 (53) 32 (17) 12 (7) 191
Stage
Limited 25 (27) 52 (58) 9 (10) 5 (5) 91
Extended 21 (21) 49 (49) 23 (23) 7 (7) 100
Manchester groups
Good 27 (33) 44 (55) 6 (7) 4 (5) 81 (42)
Intermediate 19 (20) 46 (49) 22 (23) 8 (8) 95 (50)
Poor — 11 (73) 4 (27) — 15 (8)
Age
<70 years 35 (27) 68 (51) 21 (16) 8 (6) 132 (69)
≥70 years 11 (19) 33 (56) 11 (19) 4 (6) 59 (31)
Gender
Males 17 (17) 54 (55) 20 (20) 7 (8) 98 (51)
Females 29 (30) 47 (48) 12 (12) 5 (5) 93 (49)
Chemotherapy
Anthracyclines-based 30 (28) 54 (50) 19 (18) 5 (4) 108 (57)
Platinum-based regimens 14 (30) 27 (57) 5 (11) 1 (2) 47 (25)
Carboplatin 2 (8) 10 (42) 6 (25) 6 (25) 24 (12)
Others — 12 (6)
CR: complete response, PR: partial response, SD: stable disease, PD: progressive disease.
our evidence base. An example would be a comparison of
our demographics with the Norwegian Lung Cancer Study
Group Trial [11], which reported in the middle of our study
period and has relatively wide entry criteria that included
limited and extensive disease. The age, performance status,
and stage of our patients are similar to those included in the
trial but we note we treated a signiﬁcantly higher proportion
of female patients (51 vs. 36%) with worse performance
status (PS 0/1 47% vs. 65%).
The treatment response rates documented in this study
are comparable to those reported in trials, but these trials
[12] have reported better survival outcomes. The Norwe-
gian study [11], for example, compared anthracycline and
platinum-based chemotherapy and demonstrated a sur-
vival advantage in favour of the platinum-based treatment
(median survival 7.8 vs. 10.2) months. Although the entry
criteria for this study were relatively broad, our population
included a number of patients who would not meet the
trial inclusion criteria, the biggest group being the 17%
of our patients who were not considered ﬁt for primary
chemotherapy treatment.
The national LUCADA database has been developed to
collect more detailed demographic information on patients
with lung cancer, to allow adjustments for comorbidity and
other factors to be made when comparing outcome across
England and Wales and has published its ﬁrst report [13]
with coverage extending to the majority of the population.
The data collected by this report covers a diﬀerent, but
overlapping, period to our audit and comparison suggests
the median survival reported in our series is a typical
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Figure 2: Survival in relation to Manchester scores.
outcome for UK as a whole (6 vs. 5.6 months), using current
guidelines. During the period of our audit, our unit reached
the current national guidance recommendations with 100%
of patients being reviewed by the MDT and histological
conﬁrmation rate of 83% and this compares favourable withJournal of Oncology 5
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Figure 3: Survival function in relation to chronological periods.
the LUCADA averages in 2005 of 78% and 65%, respectively.
In addition, treatment rates compare favourably, 83% of our
patients received chemotherapy; the LUCADA average being
54%. Therefore, with median age, sex ratio, performance
status, stage of disease, and comorbidities being similar, we
are disappointed that at best we demonstrate a marginal
improvement in the median survival of our patients with
SCLC (6 months) compared to LUCADA report (5.6
months).
Over the 8-year study period there were no signiﬁcant
demographic changes, though we did notice a trend towards
a higher female incidence and extensive stage disease at
initial presentation, the latter probably reﬂecting increased
accuracy of staging with the increased use of CT scanning.
During the audit period there was accumulating evidence
indicating the superiority of platinum-based treatment over
anthracyclines [11, 14, 15]. This was reﬂected in the guide-
lines published in 2005 [7] and our practice with a clear
trend towards the increased use of platinum treatment in
the third cohort of patients. There was no change in the
guideline advice on the use of radiotherapy over the study
period as the evidence demonstrating the beneﬁt of thoracic
radiotherapy [16], and prophylactic cranial irradiation [17]
had accumulated during the 1990s and was being applied
at the start of the audit period. There was no change in
the proportion of patients receiving radiotherapy over time,
though from 2003 we did participate in a study of PCI in
extensive stage patients and considered concurrent rather
than sequential thoracic radiotherapy [18, 19].
The changes in treatment practice that have occurred
overthe8yearshavebeensmall;soperhapsitisunsurprising
that they have not fed through to any measurable eﬀect
on outcome for the total population with small-cell lung
cancer. However, the bigger changes that occurred during
our audit period were driven by the NHS cancer plan, which
revolutionised the delivery of cancer treatment across the
UK. The plan focused attention on target times for access,
diagnosis, and waiting times, and signiﬁcant investment
was made to reduce the intervals between referral, ﬁrst
hospital appointment and treatment. These targets are now
being met for 96–99% of cancer patients and this audit
was able to document an improvement in the patient
pathway. Comparing in 1998–2000 with 2003–2005 there
was a reduction in the mean time from GP referral to a
management plan being agreed (from 31 to 18 days) and
in the mean time from referral to initial treatment (from
34 days 27 days. The disappointment is that we are unable
to document any signiﬁcant improvement in outcome to
correspond with this improvement.
5. Conclusion
We feel that these data reﬂect the evolution of evidence-
basedtreatment,deliveredtoanunselectedcohortofpatients
presenting to a single cancer unit. Disappointingly, we could
not document any signiﬁcant improvement in outcome for
patients over the 8-year audit period. It remains diﬃcult
to translate the survival beneﬁts reported in trials. We feel
that improvements in outcome will only come with earlier
diagnosis and improvements in the general health of our
population.
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